<DOC>
	<DOCNO>NCT01486940</DOCNO>
	<brief_summary>This trial conduct Europe South America . The aim trial compare glycaemic control insulin detemir plus insulin aspart insulin NPH plus human soluble insulin subject type 1 diabetes basal/bolus regimen .</brief_summary>
	<brief_title>Comparison Insulin Detemir Plus Insulin Aspart With Insulin NPH Plus Human Soluble Insulin Subjects With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec , insulin aspart drug combination</mesh_term>
	<mesh_term>Isophane insulin , beef</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Detemir</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin , Long-Acting</mesh_term>
	<mesh_term>Isophane Insulin , Human</mesh_term>
	<mesh_term>Insulin , Isophane</mesh_term>
	<criteria>Type 1 diabetes least 12 month Current treatment basal/bolus regimen biphasic insulin treatment least 6 month BMI equal 35 kg/m^2 HbA1c equal 12 % Proliferative retinopathy maculopathy require acute treatment Recurrent major hypoglycaemia may interfere trial participation ( judged Investigator ) Subjects know hypoglycaemic unawareness judge Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>